Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D62OSE
|
|||
| Drug Name |
FBX-101
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Krabbe disease [ICD-11: 8A44.4] | Phase 1/2 | [1] | |
| Company |
Forge Biologics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Galactocerebrosidase (GALC) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05739643) A Phase 1b Clinical Study of Intravenous AAVrh10 Vector Expressing GALC in Krabbe Subjects Who Previously Received Hematopoietic Stem Cell Transplantation (REKLAIM). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04693598) A Phase 1/2 Clinical Study of Intravenous Gene Transfer With an AAVrh10 Vector Expressing GALC in Krabbe Subjects Receiving Hematopoietic Stem Cell Transplantation (RESKUE). U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.